Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): A clinical phase II study

Cancer

Volumn 80, Issue 3, 1997, Pages 465-470

  Otto, Thomas ^a,c   Bex, Axel ^a,c   Krege, Susanne ^a,c   Walz, Peter H ^b   Rübben, Herbert ^a,c  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b District Hospital Ludenscheid   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Accelular pertussis vaccine; Antimotility factors; Carboplatin; Metastatic bladder carcinoma; Paclitaxel

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; BONE MARROW TOXICITY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REMISSION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PERTUSSIS VACCINE; REMISSION INDUCTION; URINARY BLADDER NEOPLASMS;

EID: 0030764132     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970801)80:3<465::AID-CNCR14>3.0.CO;2-V     Document Type: Article

References (20)

1. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, et al. Cisplatin, cyclophosphamid and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 1989;141:33-7.
2. Braun-Chaurasia R, Betz G, Plauz L, Salabasisis C. Mitomycin C, folinic acid and fluorouracil in locally advanced transitional cell bladder carcinoma: efficacy and toxicity. In: Taguchi T, Aigner KR, editors. Mitomycin in cancer chemotherapy today. Tokyo: Excerpta Medica, Ltd., 1991:181-6.
3. Hillcoat B, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R, et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of urothelial tract. J Clin Oncol 1989;7:706-9.
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr SW, Morse MJ, et al. M-VAC (methotrexate, vinblastme, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139:461-9.
5. RUTT. Harnwegstumorregister, Jahresbericht. Verh Dtsch Ges Urol 1995;37:665.
6. Skinner DG, Daniels JR, Russel CA. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-67.
7. Smith JA Jr., Whitemore WF Jr. Regional lymph node metastasis from bladder cancer. J Urol 1981;126:591-3.
8. Loehrer PJ, Elson P, Kuebler JP. Advanced bladder cancer: a prospective intergroup trial comparing single agent cisplatin (CDDP) vs M-VAC combination therapy (INT 0078) [meeting abstract]. Proc Am Soc Clin Oncol 1990;9:A511.
9. Logothetis CJ, Dexeus FH, Fin L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
10. De Mulder PH, Debruyne FM, Keizer HJ, Ten Bokkel Huinick W, Pauw M, Sylvester R. Randomized phase II study of methotrexate (M), cisplatin (C), and methotrexate, cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder [meeting abstract]. Eur Urol 1990; 18(Suppl 1):5.
11. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990;144:662-5.
12. Otto T, Krege S, Goepel M, Rübben H. Second line Chemotherapie beim metastasierten Harnblasenkarzinom. Urologe A 1994;51:102.
13. Logothetis CJ, Hossau E, Sella A, Dexeus FH, Amato RJ. Fluorouracil and recombinant interferon alpha 2a in the treatment of metastatic refractory urothelial tumors. J Natl Cancer Inst 1991;83:258-64.
14. McCaffrey J, Hilton S, Bajorin D, Mazumdar M, Amsterdam A, Kim B, et al. Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin based chemotherapy: a phase II trial. Proc Am Soc Clin Oncol 1995;14:233.
15. Hainsworth JD, Erland J, Peters M, Greco FA. Treatment of small cell lung cancer with taxol, carboplatin and etoposid: phase II study of an outpatient regimen. Proc Am Soc Clin Oncol 1994;13:350.
16. De Wit R, Stoter G, Blanc C, Hubert S, Verweij J. Phase II study of first-line docetaxel (Taxotere) in patients with metastatic urothelial cancer. Ann Oncol 1994;5(Suppl 8),67A: 331.
17. Bishop JF, Zalcberg J, Webster LK, Millward MJ, Zimet A, Rischin D, et al. A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) (ENG). Lung Cancer 1994;11(Suppl 1),124A:476.
18. Roth BJ, Dreicer R, Einhorn LH, Johnson DH, Smith JL, Hudes GR, et al. Paclitaxel in previously untreated advanced transitional cell carcinoma of the urothelium: a phase II trial of the ECOG. Proc Am Soc Clin Oncol 1994;13:230.
19. Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübben H, et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as prognostic factors in patients with bladder carcinoma. Cancer Res 1994;54:3120-3.
20. Otto T, Goepel M, Noll F, Rübben H, Raz A. Tumor cell motility: a novel therapeutic target in bladder cancer patients. J Urol 1995;153(Suppl 4):522A.